Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing–Remitting Multiple Sclerosis CLARITY (cas 104040-79-1) Trial and the CLARITY (cas 104040-79-1) Extension Study

Add time:07/29/2019    Source:sciencedirect.com

ObjectivesStatistical methods to adjust for treatment switching are commonly applied to randomized controlled trials (RCTs) in oncology. Nevertheless, RCTs with extension studies incorporating nonrandomized dropout require consideration of alternative adjustment methods. The current study used a recognized method and a novel method to adjust for treatment switching in relapsing–remitting multiple sclerosis (MS).

We also recommend Trading Suppliers and Manufacturers of CLARITY (cas 104040-79-1). Pls Click Website Link as below: cas 104040-79-1 suppliers

Prev:Semiotic CLARITY (cas 104040-79-1) of Case Management Model and Notation (CMMN)
Next:Exploring Correlates of Infant CLARITY (cas 104040-79-1) of Cues During Early Feeding Interactions)